Skip to content

ProACTIVE SCI Physical Activity Intervention

ProACTIVE SCI Physical Activity Coaching Intervention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03111030
Enrollment
28
Registered
2017-04-12
Start date
2017-04-28
Completion date
2018-08-01
Last updated
2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Brief summary

This study will employ a randomized, wait-list controlled trial. A total of 30 participants (15 experimental, 15 wait-list control) between 18-65 years of age who have chronic SCI ≥ 1 year prior will be recruited. Physical activity measures will be taken using wrist-based accelerometers and the Leisure Time Physical Activity Questionnaire for people with SCI (LTPAQ). Psychosocial factors will be evaluated through questionnaires. The primary health outcome measure (aPWV), and secondary cardiovascular parameters will be assessed using a combination of echocardiography and ultrasound. Fitness will be determined using a peak oxygen consumption test on an arm-cycle ergometer. All measurement will be taken at baseline and after 9 weeks following intervention commencement. Physical activity will also be sampled mid-intervention at 4 and 7 weeks. Training will involve weekly, 10-15 minute coaching sessions for 9 weeks. All pre- and post-assessments will take place at the Blusson Spinal Cord Centre at ICORD. Intervention content will be delivered in-person, over Skype or phone, and the wrist- worn accelerometers will be delivered and picked up from the participant's home during the intervention.

Detailed description

A randomized, wait-list controlled trial will be used to compare the effects of tailored PA coaching sessions versus no coaching on PA behaviour, psychosocial factors, and health outcomes. Eligible individuals will be randomly assigned (1:1) to either the experimental (PA coaching sessions) or wait-list control condition. Matched randomization based on baseline physical activity levels will be used. The randomization sequence will be generated by a research assistant independent of the trial. Day 1 testing measures include vascular measures (arterial pulse wave velocity, arterial structure; 30 minutes), cardiac structure and function measures (30 minutes), a peak oxygen uptake test (60 minutes), for a total duration of 2 hours. Participants will be given an accelerometer to wear for the 6-day monitoring period (6.1.2) after which they will return for Day 2 testing. Day 2 testing measures include administration of the LTPAQ (5 minutes), administration of the demographics and Health Action Process Approach model questionnaire (25 minutes), and a measurement of energy expenditure at different sub-maximal wheeling speeds to calibrate MVPA cut-points (30 minutes) and at baseline, the first PA coaching session will be administered (60 minutes) whereas at post-test a semi-structured interview will be administered (60 minutes). Total duration of day 2 testing will be 2 hours. The intervention protocol is described below. During the intervention, physical activity will be sampled at two time points; accelerometer and PARA SCI data will be taken during week 4 and week 7. INTERVENTION Intervention Protocol: Experimental participants will receive weekly PA coaching sessions. Each session will be 10-15 minutes in duration and delivered either face to face, over Skype, or when the former modes are unavailable, over the phone. Additionally, supplemental resources may be emailed to the participants based on need throughout the intervention. Participants' motivation to exercise will first be determined according to stages of the HAPA model. Those who identify as pre-intenders (no intention to exercise) will receive intervention strategies that focus on changing motivation to be physically active. Those identified as intenders (willing to exercise but have not started) will focus on providing resources and behavioural strategies to commence physical activity. Lastly, those identified as actors (already exercising) will receive intervention strategies that help participants maintain or improve PA behaviour. For those in the intender or actor stage, the intervention aims to promote the international SCI PA guidelines to promote fitness (at least 20 minutes of moderate vigorous aerobic activity twice/week and strength training twice/week). For those exceeding the fitness guidelines, the international SCI PA guidelines to promote health are promoted (at least 30 minutes of moderate to vigorous aerobic activity three times/week and strength training twice/week). However, these aims will be modified based on the individual's baseline PA. During the first visit, participants' baseline PA levels will be reviewed and an appropriate PA goal to achieve in the following month will be formed. Ultimately, the goal is the decision of the participant. Following goal setting, barriers to participating in PA will be identified. The interventionist will select intervention strategies based on the identified barriers. A pre-formed chart of corresponding intervention strategies (e.g. use of behaviour change techniques, referral to facilities or peers, suggesting at-home exercises) was developed to aid this pairing process (Appendix A). These intervention strategies are accompanied by a comprehensive toolkit based from the HAPA model (Appendix B). In brief, the toolkit advises on three key strategies for promoting PA to people with SCI: i) education, ii) referral, iii) tailored PA prescription. Remaining weekly coaching sessions will review participants' progress and barriers to discuss new goals and strategies as outlined above. Control Participants: Control participants will complete baseline and post-testing only. Following completion of post-test measures they will be administered the same PA coaching session as the intervention group, with post-test measures being repeated upon intervention completion.

Interventions

BEHAVIORALProacTive SCI

Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include: 1. An assessment of motivated the participant is to be physically active 2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided. B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles. 3. Progress and barriers will be reassessed and discussed.

Sponsors

Rick Hansen Institute
CollaboratorOTHER
Ontario Neurotrauma Foundation
CollaboratorOTHER
International Collaboration on Repair Discoveries
CollaboratorOTHER
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Individuals must be competent to give informed consent, * be able to propel an arm ergometer.

Exclusion criteria

* History and/or symptoms of CVD or cardiopulmonary problems/disease. * Major trauma or surgery within the last 6 months. * Active Stage 3 or 4 pressure ulcer (based on the National Pressure Ulcer Advisory Panel classification) * Recent (within 1 year) history of lower-extremity or non-union fracture * Any unstable medical/psychiatric condition or substance abuse disorder that is likely to affect their ability to complete this study. * Individuals with active medical issues such as pressure sores, urinary tract infections, hypertension, or heart disorders. * Any cognitive dysfunction or language barrier that would prevent subjects from following English instructions. * Subjects may be excluded at the discretion of the principal investigator due to other, unforeseen, safety issues.

Design outcomes

Primary

MeasureTime frameDescription
Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Baseline, week 4, week 7, week 10, 6 month follow upParticipants will be asked to complete a questionnaire, guided by the co-investigator (Jasmin Ma), that asks the participant to recall in the last 7 days how many days and for how long leisure time physical activity was performed. The recall assessment will take approximately 5 minutes to complete.
Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodBaseline, week 4, week 7, week 10Participants will be fitted with a wrist-based tri-axial accelerometer to be worn 24 hours a day for 6 days in order to determine intensity and amount of PA. They will keep a detailed PA diary recording all leisure time PA performed during the day. The primary outcome will be total vector magnitude (VM) accelerometer counts from a tri-axial wrist-worn accelerometer (GT9X, ActiGraph LLC, FL). During the intervention, the accelerometer will be picked up and dropped off to the participant's home to decrease burden. Text or email reminders (i.e. Please don't forget to wear your accelerometer today) will be used to promote adherence to accelerometer wear.

Secondary

MeasureTime frameDescription
Change in Pulse Wave VelocityBaseline, 9 weeks from intervention start (week 10)aPWV (cm/s) is calculated by dividing the distance between measurement sites, by the pulse transit time. Distance between the carotid and femoral arteries will be measured using measuring tape along the surface of the body, held parallel to the testing table. The pulse transit is determined from the arterial blood pressure waves, which are collected at each arterial site. A pen-like device (model SPT-301; Millar Instruments Inc., Houston, TX) will be applied to the carotid and femoral arterial sites using a light pressure to obtain arterial pressure waves. Heart rate will be recorded using a single-lead (lead I) electrocardiogram (ECG) (model ML 123, ADInstruments Inc., Colorado Springs, CO).
Change in Arterial Structure: Wall ThicknessBaseline, 9 weeks from intervention start (week 10)Common carotid arterial images will be collected using B-mode ultrasound (INFO) for 10 cardiac cycles. Images will be analyzed using internal ultrasound software to determine lumen diameter and intima-media thickness.
Change in End Systolic VolumeBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Change in End Diastolic VolumeBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Change in Intraventricular Septum DiameterBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Change in Ventricular Internal DiameterBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Change in Health Action Process Approach Model MeasureBaseline, 9 weeks from intervention start (week 10)This survey will examine psychological factors that may affect PA participation. The survey will be recorded either electronically or with pen and paper depending on the respondent's preference. Survey will take approximately 25 minutes to complete, and will assess constructs related to exercise such as perceived risks, self- efficacy, planning, and social support. The demographics questionnaire will also be administered with this measure. All items will be assessed on a 7-point Likert scale ranging from 1 = strongly disagree to 7 = strongly agree. Higher scores indicate a better outcome.
Change in Ejection FractionBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Change in Cardiac OutputBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Change in Fractional ShorteningBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. Longitudinal strain will be used to measure change in fractional shortening.
Change in Diastolic FunctionBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. E'/A' (ratio between early diastolic septal tissue velocity and late diastolic septal tissue velocity) will be used to measure change in diastolic function.
Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)Baseline, 9 weeks from intervention start (week 10)Participants will perform a graded arm ergometer test on an electronically braked arm ergometer. For participants with tetraplegia who have limited handgrip function, gloves will be used to secure hands to the ergometer handles. Participants will be instructed to maintain a cycling rate of 50 revolutions per minute (rpm) for the duration of the test. After an initial warm-up at 0W, power output will be increased each minute at a rate of 2-5 W/min for participants with tetraplegia, or 10 W/min for participants with paraplegia, until volitional exhaustion (i.e. dropping below 30 rpm). Oxygen consumption will be recorded on a breath-by-breath basis for the duration of the test and reported as rolling 30-second averages sampled at 5-second intervals as per consensus recommendations. All outcome data are reported here: https://doi.org/10.1007/s40279-019-01118-5
Change in Systolic FunctionBaseline, 9 weeks from intervention start (week 10)Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. LV stroke volume will be used to measure change in systolic function.
Number of Participants Participating in Qualitative Interviews9 weeks from intervention start (week 10)A semi-structured interview will be conducted at the end of the intervention to understand what components were and were not effective. Data will not be recorded. This feedback will be used to improve future iterations of the intervention. There is no associated scale with this measurement.

Countries

Canada

Participant flow

Participants by arm

ArmCount
ProacTive SCI
Individualized physical activity coaching sessions ProacTive SCI: Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include: 1. An assessment of motivated the participant is to be physically active 2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided. B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles. 3. Progress and barriers will be reassessed and discussed.
14
Wait-list Control
Standard care, receiving physical activity coaching sessions after completing post-testing
14
Total28

Baseline characteristics

CharacteristicTotalWait-list ControlProacTive SCI
Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)1.14 L/min
STANDARD_DEVIATION 0.41
1.13 L/min
STANDARD_DEVIATION 0.43
1.15 L/min
STANDARD_DEVIATION 0.36
Age, Continuous45.68 years
STANDARD_DEVIATION 11.93
45.57 years
STANDARD_DEVIATION 10.49
45.79 years
STANDARD_DEVIATION 13.63
Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)243 Total LTPA min/week
STANDARD_DEVIATION 248
274 Total LTPA min/week
STANDARD_DEVIATION 300
212 Total LTPA min/week
STANDARD_DEVIATION 195
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants2 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
4 Participants2 Participants2 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
22 Participants10 Participants12 Participants
Region of Enrollment
Canada
28 participants14 participants14 participants
Sex: Female, Male
Female
13 Participants8 Participants5 Participants
Sex: Female, Male
Male
15 Participants6 Participants9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 140 / 14
other
Total, other adverse events
0 / 140 / 14
serious
Total, serious adverse events
0 / 140 / 14

Outcome results

Primary

Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)

Participants will be asked to complete a questionnaire, guided by the co-investigator (Jasmin Ma), that asks the participant to recall in the last 7 days how many days and for how long leisure time physical activity was performed. The recall assessment will take approximately 5 minutes to complete.

Time frame: Baseline, week 4, week 7, week 10, 6 month follow up

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Week 7370 Total LTPA min/weekStandard Deviation 258
ProacTive SCIChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Baseline212 Total LTPA min/weekStandard Deviation 195
ProacTive SCIChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Week 4393 Total LTPA min/weekStandard Deviation 413
ProacTive SCIChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)6 months FU348 Total LTPA min/weekStandard Deviation 269
ProacTive SCIChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Week 10405 Total LTPA min/weekStandard Deviation 364
Wait-list ControlChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)6 months FUNA Total LTPA min/week
Wait-list ControlChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Week 4NA Total LTPA min/week
Wait-list ControlChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Week 7NA Total LTPA min/week
Wait-list ControlChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Week 10147 Total LTPA min/weekStandard Deviation 192
Wait-list ControlChange in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)Baseline274 Total LTPA min/weekStandard Deviation 300
Primary

Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period

Participants will be fitted with a wrist-based tri-axial accelerometer to be worn 24 hours a day for 6 days in order to determine intensity and amount of PA. They will keep a detailed PA diary recording all leisure time PA performed during the day. The primary outcome will be total vector magnitude (VM) accelerometer counts from a tri-axial wrist-worn accelerometer (GT9X, ActiGraph LLC, FL). During the intervention, the accelerometer will be picked up and dropped off to the participant's home to decrease burden. Text or email reminders (i.e. Please don't forget to wear your accelerometer today) will be used to promote adherence to accelerometer wear.

Time frame: Baseline, week 4, week 7, week 10

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodWeek 7659000 Accelerometer total VM countsStandard Deviation 338000
ProacTive SCIChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodBaseline562000 Accelerometer total VM countsStandard Deviation 188000
ProacTive SCIChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodWeek 10702000 Accelerometer total VM countsStandard Deviation 267000
ProacTive SCIChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodWeek 4593000 Accelerometer total VM countsStandard Deviation 307000
Wait-list ControlChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodWeek 10598000 Accelerometer total VM countsStandard Deviation 390000
Wait-list ControlChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodWeek 7NA Accelerometer total VM counts
Wait-list ControlChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodWeek 4NA Accelerometer total VM counts
Wait-list ControlChange in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring PeriodBaseline848000 Accelerometer total VM countsStandard Deviation 759000
Secondary

Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)

Participants will perform a graded arm ergometer test on an electronically braked arm ergometer. For participants with tetraplegia who have limited handgrip function, gloves will be used to secure hands to the ergometer handles. Participants will be instructed to maintain a cycling rate of 50 revolutions per minute (rpm) for the duration of the test. After an initial warm-up at 0W, power output will be increased each minute at a rate of 2-5 W/min for participants with tetraplegia, or 10 W/min for participants with paraplegia, until volitional exhaustion (i.e. dropping below 30 rpm). Oxygen consumption will be recorded on a breath-by-breath basis for the duration of the test and reported as rolling 30-second averages sampled at 5-second intervals as per consensus recommendations. All outcome data are reported here: https://doi.org/10.1007/s40279-019-01118-5

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIAerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)Baseline1.16 L/minStandard Deviation 0.38
ProacTive SCIAerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)Week 101.30 L/minStandard Deviation 0.43
Wait-list ControlAerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)Baseline1.13 L/minStandard Deviation 0.46
Wait-list ControlAerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)Week 101.06 L/minStandard Deviation 0.4
Secondary

Change in Arterial Structure: Wall Thickness

Common carotid arterial images will be collected using B-mode ultrasound (INFO) for 10 cardiac cycles. Images will be analyzed using internal ultrasound software to determine lumen diameter and intima-media thickness.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Arterial Structure: Wall ThicknessBaseline0.62 mmStandard Deviation 0.16
ProacTive SCIChange in Arterial Structure: Wall ThicknessWeek 100.61 mmStandard Deviation 0.15
Wait-list ControlChange in Arterial Structure: Wall ThicknessBaseline0.56 mmStandard Deviation 0.07
Wait-list ControlChange in Arterial Structure: Wall ThicknessWeek 100.56 mmStandard Deviation 0.07
Secondary

Change in Cardiac Output

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Cardiac OutputBaseline3.22 L/minStandard Deviation 0.78
ProacTive SCIChange in Cardiac OutputWeek 103.13 L/minStandard Deviation 0.63
Wait-list ControlChange in Cardiac OutputBaseline3.05 L/minStandard Deviation 0.87
Wait-list ControlChange in Cardiac OutputWeek 103.13 L/minStandard Deviation 0.96
Secondary

Change in Diastolic Function

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. E'/A' (ratio between early diastolic septal tissue velocity and late diastolic septal tissue velocity) will be used to measure change in diastolic function.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Diastolic FunctionBaseline0.99 RatioStandard Deviation 0.21
ProacTive SCIChange in Diastolic FunctionWeek 101.02 RatioStandard Deviation 0.32
Wait-list ControlChange in Diastolic FunctionBaseline1.10 RatioStandard Deviation 0.33
Wait-list ControlChange in Diastolic FunctionWeek 101.14 RatioStandard Deviation 0.36
Secondary

Change in Ejection Fraction

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Ejection FractionBaseline57 % of blood ejected per contractionStandard Deviation 3
ProacTive SCIChange in Ejection FractionWeek 1056 % of blood ejected per contractionStandard Deviation 3
Wait-list ControlChange in Ejection FractionBaseline57 % of blood ejected per contractionStandard Deviation 3
Wait-list ControlChange in Ejection FractionWeek 1058 % of blood ejected per contractionStandard Deviation 3
Secondary

Change in End Diastolic Volume

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in End Diastolic VolumeBaseline87 mlStandard Deviation 18
ProacTive SCIChange in End Diastolic VolumeWeek 1086 mlStandard Deviation 14
Wait-list ControlChange in End Diastolic VolumeBaseline84 mlStandard Deviation 20
Wait-list ControlChange in End Diastolic VolumeWeek 1082 mlStandard Deviation 18
Secondary

Change in End Systolic Volume

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in End Systolic VolumeBaseline38 mlStandard Deviation 9
ProacTive SCIChange in End Systolic VolumeWeek 1038 mlStandard Deviation 9
Wait-list ControlChange in End Systolic VolumeBaseline36 mlStandard Deviation 9
Wait-list ControlChange in End Systolic VolumeWeek 1035 mlStandard Deviation 8
Secondary

Change in Fractional Shortening

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. Longitudinal strain will be used to measure change in fractional shortening.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Fractional ShorteningBaseline-19.0 % change from original lengthStandard Deviation 2.6
ProacTive SCIChange in Fractional ShorteningWeek 10-19.2 % change from original lengthStandard Deviation 2.7
Wait-list ControlChange in Fractional ShorteningBaseline-17.5 % change from original lengthStandard Deviation 4.3
Wait-list ControlChange in Fractional ShorteningWeek 10-18.1 % change from original lengthStandard Deviation 3.3
Secondary

Change in Health Action Process Approach Model Measure

This survey will examine psychological factors that may affect PA participation. The survey will be recorded either electronically or with pen and paper depending on the respondent's preference. Survey will take approximately 25 minutes to complete, and will assess constructs related to exercise such as perceived risks, self- efficacy, planning, and social support. The demographics questionnaire will also be administered with this measure. All items will be assessed on a 7-point Likert scale ranging from 1 = strongly disagree to 7 = strongly agree. Higher scores indicate a better outcome.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Health Action Process Approach Model MeasureBarrier self-efficacy (Baseline)5.0 score on a scaleStandard Deviation 1.2
ProacTive SCIChange in Health Action Process Approach Model MeasureAerobic exercise task self-efficacy (Week 10)4.7 score on a scaleStandard Deviation 1.2
ProacTive SCIChange in Health Action Process Approach Model MeasureStrength exercise task self-efficacy (Baseline)3.9 score on a scaleStandard Deviation 1.6
ProacTive SCIChange in Health Action Process Approach Model MeasureAerobic exercise task self-efficacy (Baseline)3.4 score on a scaleStandard Deviation 1.9
ProacTive SCIChange in Health Action Process Approach Model MeasureStrength exercise task self-efficacy (Week 10)5.6 score on a scaleStandard Deviation 1.2
ProacTive SCIChange in Health Action Process Approach Model MeasureBarrier self-efficacy (Week 10)5.7 score on a scaleStandard Deviation 0.8
ProacTive SCIChange in Health Action Process Approach Model MeasureScheduling self-efficacy (Baseline)4.9 score on a scaleStandard Deviation 1.5
ProacTive SCIChange in Health Action Process Approach Model MeasureInstrumental outcome expectancies (Baseline)6.5 score on a scaleStandard Deviation 0.6
ProacTive SCIChange in Health Action Process Approach Model MeasurePlanning self-efficacy (Week 10)6.0 score on a scaleStandard Deviation 0.5
ProacTive SCIChange in Health Action Process Approach Model MeasureAction planning (Baseline)3.7 score on a scaleStandard Deviation 1.9
ProacTive SCIChange in Health Action Process Approach Model MeasureMonitoring (Baseline)4.5 score on a scaleStandard Deviation 1.6
ProacTive SCIChange in Health Action Process Approach Model MeasureScheduling self-efficacy (Week 10)5.7 score on a scaleStandard Deviation 1.3
ProacTive SCIChange in Health Action Process Approach Model MeasureAffective outcome expectancies (Week 10)5.6 score on a scaleStandard Deviation 1
ProacTive SCIChange in Health Action Process Approach Model MeasureAction planning (Week 10)6.8 score on a scaleStandard Deviation 0.4
ProacTive SCIChange in Health Action Process Approach Model MeasureIntentions (Baseline)6.1 score on a scaleStandard Deviation 1.1
ProacTive SCIChange in Health Action Process Approach Model MeasureRisk perceptions (Baseline)2.5 score on a scaleStandard Deviation 1.6
ProacTive SCIChange in Health Action Process Approach Model MeasureMonitoring (Week 10)6.3 score on a scaleStandard Deviation 0.8
ProacTive SCIChange in Health Action Process Approach Model MeasureCoping self-efficacy (Baseline)6.0 score on a scaleStandard Deviation 0.8
ProacTive SCIChange in Health Action Process Approach Model MeasureIntentions (Week 10)6.8 score on a scaleStandard Deviation 0.4
ProacTive SCIChange in Health Action Process Approach Model MeasureCoping self-efficacy (Week 10)6.3 score on a scaleStandard Deviation 0.7
ProacTive SCIChange in Health Action Process Approach Model MeasureSocial support (Baseline)2.2 score on a scaleStandard Deviation 1
ProacTive SCIChange in Health Action Process Approach Model MeasureAffective outcome expectancies (Baseline)5.1 score on a scaleStandard Deviation 1.3
ProacTive SCIChange in Health Action Process Approach Model MeasureSocial support (Week 10)2.8 score on a scaleStandard Deviation 0.9
ProacTive SCIChange in Health Action Process Approach Model MeasurePlanning self-efficacy (Baseline)5.9 score on a scaleStandard Deviation 0.8
ProacTive SCIChange in Health Action Process Approach Model MeasurePresence of barriers (Baseline)5.7 score on a scaleStandard Deviation 1.5
ProacTive SCIChange in Health Action Process Approach Model MeasurePresence of barriers (Week 10)6.1 score on a scaleStandard Deviation 1.1
ProacTive SCIChange in Health Action Process Approach Model MeasureKnowledge (Baseline)5.9 score on a scaleStandard Deviation 1.1
ProacTive SCIChange in Health Action Process Approach Model MeasureRisk perceptions (Week 10)2.8 score on a scaleStandard Deviation 1.6
ProacTive SCIChange in Health Action Process Approach Model MeasureKnowledge (Week 10)6.7 score on a scaleStandard Deviation 0.4
ProacTive SCIChange in Health Action Process Approach Model MeasureInstrumental outcome expectancies (Week 10)6.8 score on a scaleStandard Deviation 0.3
Wait-list ControlChange in Health Action Process Approach Model MeasureKnowledge (Week 10)4.4 score on a scaleStandard Deviation 2
Wait-list ControlChange in Health Action Process Approach Model MeasureAffective outcome expectancies (Week 10)5.4 score on a scaleStandard Deviation 1
Wait-list ControlChange in Health Action Process Approach Model MeasureInstrumental outcome expectancies (Week 10)6.3 score on a scaleStandard Deviation 0.8
Wait-list ControlChange in Health Action Process Approach Model MeasureAerobic exercise task self-efficacy (Baseline)4.1 score on a scaleStandard Deviation 1.7
Wait-list ControlChange in Health Action Process Approach Model MeasureAerobic exercise task self-efficacy (Week 10)3.6 score on a scaleStandard Deviation 1.6
Wait-list ControlChange in Health Action Process Approach Model MeasureIntentions (Baseline)6.5 score on a scaleStandard Deviation 0.7
Wait-list ControlChange in Health Action Process Approach Model MeasurePlanning self-efficacy (Week 10)6.8 score on a scaleStandard Deviation 0.4
Wait-list ControlChange in Health Action Process Approach Model MeasureBarrier self-efficacy (Baseline)4.4 score on a scaleStandard Deviation 1
Wait-list ControlChange in Health Action Process Approach Model MeasureScheduling self-efficacy (Week 10)5.5 score on a scaleStandard Deviation 1.1
Wait-list ControlChange in Health Action Process Approach Model MeasureMonitoring (Week 10)4.4 score on a scaleStandard Deviation 1.3
Wait-list ControlChange in Health Action Process Approach Model MeasureCoping self-efficacy (Week 10)6.3 score on a scaleStandard Deviation 0.7
Wait-list ControlChange in Health Action Process Approach Model MeasurePresence of barriers (Baseline)5.5 score on a scaleStandard Deviation 1.3
Wait-list ControlChange in Health Action Process Approach Model MeasurePresence of barriers (Week 10)5.0 score on a scaleStandard Deviation 1.8
Wait-list ControlChange in Health Action Process Approach Model MeasureAffective outcome expectancies (Baseline)5.7 score on a scaleStandard Deviation 0.9
Wait-list ControlChange in Health Action Process Approach Model MeasureInstrumental outcome expectancies (Baseline)6.5 score on a scaleStandard Deviation 0.9
Wait-list ControlChange in Health Action Process Approach Model MeasureRisk perceptions (Week 10)2.5 score on a scaleStandard Deviation 1.1
Wait-list ControlChange in Health Action Process Approach Model MeasureStrength exercise task self-efficacy (Baseline)3.7 score on a scaleStandard Deviation 1.6
Wait-list ControlChange in Health Action Process Approach Model MeasureStrength exercise task self-efficacy (Week 10)3.2 score on a scaleStandard Deviation 1.8
Wait-list ControlChange in Health Action Process Approach Model MeasureIntentions (Week 10)6.3 score on a scaleStandard Deviation 1.2
Wait-list ControlChange in Health Action Process Approach Model MeasurePlanning self-efficacy (Baseline)6.2 score on a scaleStandard Deviation 1.1
Wait-list ControlChange in Health Action Process Approach Model MeasureBarrier self-efficacy (Week 10)4.7 score on a scaleStandard Deviation 1.1
Wait-list ControlChange in Health Action Process Approach Model MeasureScheduling self-efficacy (Baseline)5.3 score on a scaleStandard Deviation 1.2
Wait-list ControlChange in Health Action Process Approach Model MeasureAction planning (Baseline)3.8 score on a scaleStandard Deviation 2
Wait-list ControlChange in Health Action Process Approach Model MeasureAction planning (Week 10)3.6 score on a scaleStandard Deviation 2.3
Wait-list ControlChange in Health Action Process Approach Model MeasureMonitoring (Baseline)4.4 score on a scaleStandard Deviation 1.4
Wait-list ControlChange in Health Action Process Approach Model MeasureCoping self-efficacy (Baseline)5.8 score on a scaleStandard Deviation 1.2
Wait-list ControlChange in Health Action Process Approach Model MeasureSocial support (Baseline)2.0 score on a scaleStandard Deviation 0.8
Wait-list ControlChange in Health Action Process Approach Model MeasureSocial support (Week 10)1.7 score on a scaleStandard Deviation 0.5
Wait-list ControlChange in Health Action Process Approach Model MeasureKnowledge (Baseline)5.2 score on a scaleStandard Deviation 1.9
Wait-list ControlChange in Health Action Process Approach Model MeasureRisk perceptions (Baseline)2.5 score on a scaleStandard Deviation 1.3
Secondary

Change in Intraventricular Septum Diameter

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.

Time frame: Baseline, 9 weeks from intervention start (week 10)

Population: This was not measured or reported.

Secondary

Change in Pulse Wave Velocity

aPWV (cm/s) is calculated by dividing the distance between measurement sites, by the pulse transit time. Distance between the carotid and femoral arteries will be measured using measuring tape along the surface of the body, held parallel to the testing table. The pulse transit is determined from the arterial blood pressure waves, which are collected at each arterial site. A pen-like device (model SPT-301; Millar Instruments Inc., Houston, TX) will be applied to the carotid and femoral arterial sites using a light pressure to obtain arterial pressure waves. Heart rate will be recorded using a single-lead (lead I) electrocardiogram (ECG) (model ML 123, ADInstruments Inc., Colorado Springs, CO).

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Pulse Wave VelocityBaseline10.6 cm/sStandard Deviation 2.9
ProacTive SCIChange in Pulse Wave VelocityWeek 109.7 cm/sStandard Deviation 2.5
Wait-list ControlChange in Pulse Wave VelocityBaseline8.0 cm/sStandard Deviation 2
Wait-list ControlChange in Pulse Wave VelocityWeek 108.2 cm/sStandard Deviation 1.9
Secondary

Change in Systolic Function

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. LV stroke volume will be used to measure change in systolic function.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Systolic FunctionBaseline49 mlStandard Deviation 9
ProacTive SCIChange in Systolic FunctionWeek 1049 mlStandard Deviation 6
Wait-list ControlChange in Systolic FunctionBaseline48 mlStandard Deviation 11
Wait-list ControlChange in Systolic FunctionWeek 1047 mlStandard Deviation 10
Secondary

Change in Ventricular Internal Diameter

Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.

Time frame: Baseline, 9 weeks from intervention start (week 10)

ArmMeasureGroupValue (MEAN)Dispersion
ProacTive SCIChange in Ventricular Internal DiameterBaseline42 mmStandard Deviation 5
ProacTive SCIChange in Ventricular Internal DiameterWeek 1043 mmStandard Deviation 4
Wait-list ControlChange in Ventricular Internal DiameterBaseline43 mmStandard Deviation 10
Wait-list ControlChange in Ventricular Internal DiameterWeek 1044 mmStandard Deviation 4
Secondary

Number of Participants Participating in Qualitative Interviews

A semi-structured interview will be conducted at the end of the intervention to understand what components were and were not effective. Data will not be recorded. This feedback will be used to improve future iterations of the intervention. There is no associated scale with this measurement.

Time frame: 9 weeks from intervention start (week 10)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
ProacTive SCINumber of Participants Participating in Qualitative Interviews14 Participants
Wait-list ControlNumber of Participants Participating in Qualitative Interviews0 Participants

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026